Suchen
CervoMed Inc
CRVOZur Watchlist hinzufügen
3.690USD
+0.590+19.03%
Handelsschluss 07/01, 16:00（ET）Kurse um 15 Minuten verzögert
49.91MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über CervoMed Inc Unternehmen
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
CervoMed Inc Informationen
BörsenkürzelCRVO
Name des UnternehmensCervoMed Inc
IPO-datumNov 09, 2016
CEOAlam (John J)
Anzahl der mitarbeiter15
WertpapierartOrdinary Share
GeschäftsjahresendeNov 09
Addresse20 Park Plaza, Suite 424
StadtBOSTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02116
Telefon16177444400
Websitehttps://cervomed.com/
BörsenkürzelCRVO
IPO-datumNov 09, 2016
CEOAlam (John J)
Führungskräfte von CervoMed Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.01M
+47.47%
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
785.55K
+4.11%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Dr. Robert J. Cobuzzi, Jr.
Dr. Robert J. Cobuzzi, Jr.
Director
Director
--
--
Mr. William R. Elder
Mr. William R. Elder
Chief Financial Officer, General Counsel, Corporate Secretary
Chief Financial Officer, General Counsel, Corporate Secretary
--
--
Dr. Sylvie L. Gregoire, Pharm.D.
Dr. Sylvie L. Gregoire, Pharm.D.
Director
Director
--
--
Dr. Marwan Noel Sabbagh, M.D.
Dr. Marwan Noel Sabbagh, M.D.
Independent Director
Independent Director
--
--
Mr. Frank E. Zavrl
Mr. Frank E. Zavrl
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.01M
+47.47%
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
785.55K
+4.11%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Dr. Robert J. Cobuzzi, Jr.
Dr. Robert J. Cobuzzi, Jr.
Director
Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von CervoMed Inc?
Die fünf größten Anteilseigner von CervoMed Inc sind: Dr. Joshua S. Boger, Ph.D.
Wie viele Institutionen halten Anteile an CervoMed Inc (CRVO)?
Mit Stand vom 2026Q1 halten 130 Institutionen Anteile an CervoMed Inc, mit einem Gesamtmarktwert von etwa 1.35M, was 14.61% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -2926415.00 gestiegen.